Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 5/2009

01-05-2009 | Original Research

Effect of insulin detemir dose frequency on clinical outcomes in patients with diabetes in PREDICTIVE

Authors: Pierre Fontaine, Henri Gin, Michel Pinget, Charles Thivolet, Hélène Hanaire, Jean-Jacques Robert, Michel Marre, Srishyla Venkatanarasimhachar

Published in: Advances in Therapy | Issue 5/2009

Login to get access
Metadata
Title
Effect of insulin detemir dose frequency on clinical outcomes in patients with diabetes in PREDICTIVE
Authors
Pierre Fontaine
Henri Gin
Michel Pinget
Charles Thivolet
Hélène Hanaire
Jean-Jacques Robert
Michel Marre
Srishyla Venkatanarasimhachar
Publication date
01-05-2009
Publisher
Springer Healthcare Communications
Published in
Advances in Therapy / Issue 5/2009
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-009-0033-6

Other articles of this Issue 5/2009

Advances in Therapy 5/2009 Go to the issue

Review

Investigation of a multimarker approach to the initial assessment of patients with acute chest pain

Review

Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

Original Research

Efficacy and tolerability of eperisone and baclofen in spastic palsy: a double-blind randomized trial

Original Research

Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis

Review

Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?

Review

The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits